4.5 Article

Inhibition and deficiency of the immunoproteasome subunit LMP7 attenuates LCMV-induced meningitis

期刊

EUROPEAN JOURNAL OF IMMUNOLOGY
卷 46, 期 1, 页码 104-113

出版社

WILEY-BLACKWELL
DOI: 10.1002/eji.201545578

关键词

Cytotoxic T cells; CNS inflammation; Immunoproteasome; LMP7; Lymphocytic choriomeningitis virus

资金

  1. Swiss National Science Foundation (SNF) [31003A_138451, 149420]
  2. German Research Foundation [BA 4199/2-1, GR 1517/14-1]
  3. Swiss National Science Foundation (SNF) [31003A_138451] Funding Source: Swiss National Science Foundation (SNF)

向作者/读者索取更多资源

In addition to antigen processing, immunoproteasomes were recently shown to exert functions influencing cytokine production by monocytes and T cells, T-helper cell differentiation, and T-cell survival. Moreover, selective inhibition of the immunoproteasome subunit LMP7 ameliorated symptoms of autoimmune diseases including CD4(+) T-cell mediated EAE. In this study, we show that LMP7 also plays a crucial role in the pathogenesis of lymphocytic choriomeningitis virus (LCMV)-induced meningitis mediated by CTLs. Mice lacking functional LMP7 display delayed and reduced clinical signs of disease accompanied by a strongly decreased inflammatory infiltration into the brain. Interestingly, we found that selective inhibition and genetic deficiency of LMP7 affect the pathogenesis of LCMV-induced meningitis in a distinct manner. Our findings support the important role of LMP7 in inflammatory disorders and suggest immunoproteasome inhibition as a novel strategy against inflammation-induced neuropathology in the CNS.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Medicine, General & Internal

Central nervous system zoning: How brain barriers establish subdivisions for CNS immune privilege and immune surveillance

Steven T. Proulx, Britta Engelhardt

Summary: The central nervous system maintains a unique relationship with the immune system through brain barriers, allowing for immune surveillance and protection of neural tissue without activating immune responses unless direct injury occurs.

JOURNAL OF INTERNAL MEDICINE (2022)

Article Allergy

Azathioprine therapy induces selective NK cell depletion and IFN-g deficiency predisposing to herpesvirus reactivation

Florian Ingelfinger, Colin Sparano, David Bamert, David Reyes-Leiva, Aakriti Sethi, Lukas Rindlisbacher, Pascale Zwicky, Stefanie Kreutmair, Corinne C. Widmer, Sarah Mundt, Elena Cortes-Vicente, Sonia Tugues, Burkhard Becher, Bettina Schreiner

Summary: This study comprehensively investigates the risks and immune dysfunction associated with azathioprine therapy. Using single-cell mass and spectral flow cytometry, the specific effects of azathioprine on the systemic immune signature were analyzed. Clinical features associated with therapy were analyzed in two independent cohorts of myasthenia gravis patients. The study highlights the risk of adverse events during azathioprine therapy and suggests that monitoring natural killer cells could be valuable in clinical practice.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2023)

Article Oncology

Immunoproteasome inhibition prevents progression of castration-resistant prostate cancer

Jun Li, Nan Liu, Hong Zhou, Peng Xian, Yanping Song, Xianli Tang, Yuan Li, Michael Basler

Summary: This study found that immunoproteasome inhibition has a significant effect on suppressing the progression of castration-resistant prostate cancer (CRPC). The results showed that immunoproteasome inhibition prevents CRPC progression by suppressing inflammation and inducing apoptosis of CRPC cells through activating the unfolded protein response.

BRITISH JOURNAL OF CANCER (2023)

Article Cardiac & Cardiovascular Systems

Co-inhibition of immunoproteasome subunits LMP2 and LMP7 enables prevention of transplant arteriosclerosis

Jun Li, Shaobo Hu, Henry W. B. Johnson, Christopher J. Kirk, Peng Xian, Yanping Song, Yuan Li, Nan Liu, Marcus Groettrup, Michael Basler

Summary: This study demonstrates that co-inhibition of LMP7 and LMP2 effectively suppresses immune-mediated vascular allograft rejection and transplant arteriosclerosis. Inhibition of LMP7 and LMP2 reduces T-cell activation and function, decreases the number of immunoglobulin G-secreting cells and plasma cells, and decreases apoptosis of vascular wall cells. Thus, co-inhibition of LMP7 and LMP2 could be a promising therapeutic approach to suppress TA and allograft rejection.

CARDIOVASCULAR RESEARCH (2023)

Article Physiology

Rapid Weight Gain and Weight Differential Predict Competitive Success in 2100 Professional Combat-Sport Athletes

Vincent Baribeau, Christopher Kirk, Danny Q. Le, Arjun Bose, Ariel Mueller, Duncan French, Todd Sarge, Carl Langan-Evans, Reid Reale, Kadhiresan R. Murugappan

Summary: This study investigates the impact of rapid weight loss and gain on the success of combat-sport athletes. The results show that the amount of weight gained and the weight differential between opponents can influence the outcomes of matches, with a greater weight gain associated with a higher likelihood of victory.

INTERNATIONAL JOURNAL OF SPORTS PHYSIOLOGY AND PERFORMANCE (2023)

Article Oncology

Suppression of prostate cancer and amelioration of the immunosuppressive tumor microenvironment through selective immunoproteasome inhibition

Julia Koerner, Dennis Horvath, Franziska Oliveri, Jun Li, Michael Basler

Summary: This study evaluates the potential of immunoproteasome inhibition as a therapeutic option for hormone-refractory prostate carcinoma (PC). The results show that the immunoproteasome inhibitor ONX 0914 can inhibit tumor growth and metastasis in PC, and reduce the immunosuppressive inflammatory response in the tumor microenvironment.

ONCOIMMUNOLOGY (2023)

Review Pharmacology & Pharmacy

PLGA Particles in Immunotherapy

Dennis Horvath, Michael Basler

Summary: Poly(lactic-co-glycolic acid) (PLGA) particles are widely used and extensively studied drug delivery system with favorable properties such as good bioavailability, controlled release, and biodegradability. Loading immunomodulating drugs into PLGA particles can protect the compounds, direct the delivery, and ensure sustained and controlled release, making them an ideal platform for immunotherapy.

PHARMACEUTICS (2023)

Article Clinical Neurology

Antibodies Produced by CLL Phenotype B Cells in Patients With Myasthenia Gravis Are Not Directed Against Neuromuscular Endplates

Florian Ingelfinger, Michael Kramer, Mirjam Lutz, Corinne C. Widmer, Luca Piccoli, Stefanie Kreutmair, Tobias Wertheimer, Mark Woodhall, Patrick Waters, Federica Sallusto, Antonio Lanzavecchia, Sarah Mundt, Burkhard Becher, Bettina Schreiner

Summary: This study suggests that myasthenia gravis (MG) may be associated with hematologic malignancies such as chronic lymphocytic leukemia (CLL). It is unclear whether the leukemic B cells are directly responsible for the autoimmune response in patients with MG and CLL. However, treatment with the anti-CD20 therapy obinutuzumab has shown potential in effectively treating AChR(+) MG.

NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2023)

Article Biology

The ubiquitin-like modifier FAT10 is degraded by the 20S proteasome in vitro but not in cellulo

Franziska Oliveri, Steffen Johannes Keller, Heike Goebel, Gerardo Omar Alvarez Salinas, Michael Basler

Summary: Ubiquitin-independent protein degradation via the 20S proteasome without the 19S regulatory particle has gained increasing attention. This study investigated the degradation of FAT10 by the 20S proteasome. It was found that FAT10 was rapidly degraded by purified 20S proteasomes in vitro due to its weak folding and N-terminally disordered tail. In cellulo experiments confirmed that the degradation of FAT10 strongly depended on functional 26S proteasome. Therefore, cautious interpretation is required when studying 20S proteasome function in vitro.

LIFE SCIENCE ALLIANCE (2023)

Article Neurosciences

IL-12 sensing in neurons induces neuroprotective CNS tissue adaptation and attenuates neuroinflammation in mice

Myrto Andreadou, Florian Ingelfinger, Donatella De Feo, Teresa L. M. Cramer, Selma Tuzlak, Ekaterina Friebel, Bettina Schreiner, Pascale Eede, Shirin Schneeberger, Maria Geesdorf, Frederike Ridder, Christina A. Welsh, Laura Power, Daniel Kirschenbaum, Shiva K. Tyagarajan, Melanie Greter, Frank L. Heppner, Sarah Mundt, Burkhard Becher

Summary: This study reveals that IL-12-induced neuroprotective tissue adaptation in autoimmune conditions of the central nervous system is mediated by IL-12-sensing neurons. The research provides experimental evidence from mice and human brain tissue and uncovers the mechanisms underlying IL-12's neuroprotective effects, which prevent neurodegeneration and maintain CNS integrity.

NATURE NEUROSCIENCE (2023)

Article Biochemistry & Molecular Biology

scTEA-db: a comprehensive database of novel terminal exon isoforms identified from human single cell transcriptomes

Miguel Barquin, Ian U. Kouzel, Beat Ehrmann, Michael Basler, Andreas J. Gruber

Summary: This study presents a single cell-based Terminal Exon Annotation database (scTEA-db), which provides yet unannotated terminal exons and associated transcript isoforms for studying their biological role in cell identity and function.

NUCLEIC ACIDS RESEARCH (2023)

Article Hospitality, Leisure, Sport & Tourism

A 5-Year Analysis of Age, Stature and Armspan in Mixed Martial Arts

Christopher Kirk

Summary: Athlete stature and armspan do not provide an advantage in mixed martial arts (MMA). Younger athletes tend to win more in divisions with diverse skill requirements.

RESEARCH QUARTERLY FOR EXERCISE AND SPORT (2023)

Meeting Abstract Oncology

KZR-540 IS A NOVEL ORAL SMALL MOLECULE INHIBITOR OF SEC61 COTRANSLATIONAL TRANSLOCATION THAT POTENTLY AND SELECTIVELY BLOCKS PD-1 EXPRESSION

Cristina Delgado-Martin, Neel Anand, Janet Anderl, Chengguo Dong, Andrea Fan, Ying Fang, Christopher Kirk, Tony Muchamuel, Yu Qian, Jinhai Wang, Jennifer Whang, Patricia Zuno-Mitchell

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)

Meeting Abstract Oncology

Sec61 inhibitor KZR-834, an anti-cancer agent, exhibits immunomodulatory activity and combines with PD-1 blockade to further enhance immune responses.

Jennifer A. Whang, Andrea Fan, Jing Jiang, Christopher J. Kirk, Tony Muchamuel

CANCER RESEARCH (2022)

暂无数据